Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?

被引：1
|
作者：
Calvo Romero, J. M. [1 ]
机构：
[1] Hosp Ciudad Coria, Med Interna Serv, Coria, Caceres, Spain
来源：
REVISTA CLINICA ESPANOLA | 2011年 / 211卷 / 03期
关键词：
Dabigatran; Direct thrombin inhibitor; Vitamin K antagonist; Atrial fibrillation; INTERNATIONAL NORMALIZED RATIO; DIRECT THROMBIN INHIBITOR; ORAL ANTICOAGULATION; RISK STRATIFICATION; PREDICTING STROKE; GENERAL-PRACTICE; WARFARIN; THERAPY; MANAGEMENT; ETEXILATE;
D O I：
10.1016/j.rce.2010.12.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with atrial fibrillation (AF) at risk of stroke are not always anticoagulated with vitamin K antagonists (VKA) despite lack of contraindication. Dabigatran, an oral direct thrombin inhibitor, is a new option with proven safety and effectiveness in these patients. The advantages of dabigatran are its more predictable response, obviating coagulation monitoring and possible lower frequency of bleedings. Its drawbacks are cost, lack of antidote and long-term data, frequency of dyspepsia and the twice daily dosage. (C) 2011 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码：142 / 146
页数：5
相关论文
共 50 条
  • [41] Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study
    Larsen, Torben Bjerregaard
    Rasmussen, Lars Hvilsted
    Gorst-Rasmussen, Anders
    Skjoth, Flemming
    Lane, Deirdre A.
    Lip, Gregory Y. H.
    AMERICAN JOURNAL OF MEDICINE, 2014, 127 (12) : 1172 - +
  • [42] Hemopericardium under dabigatran for stroke prevention in atrial fibrillation
    Stoellberger, Claudia
    Heger, Maria
    Finsterer, Josef
    BLOOD COAGULATION & FIBRINOLYSIS, 2017, 28 (02) : 185 - 188
  • [43] Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation
    Rillig, Andreas
    Lin, Tina
    Plesman, Joaquina
    Heeger, Christian-H.
    Lemes, Christine
    Metzner, Andreas
    Mathew, Shibu
    Wissner, Erik
    Wohlmuth, Peter
    Ouyang, Feifan
    Kuck, Karl-Heinz
    Tilz, Roland Richard
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2016, 27 (02) : 147 - 153
  • [44] Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation
    Bisson, Arnaud
    Angoulvant, Denis
    Philippart, Raphael
    Clementy, Nicolas
    Babuty, Dominique
    Fauchier, Laurent
    ADVANCES IN THERAPY, 2017, 34 (06) : 1283 - 1290
  • [45] Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease
    Potpara, Tatjana S.
    Jokic, Vera
    Dagres, Nikolaos
    Larsen, Torben B.
    Lane, Deirdre A.
    Hindricks, Gerhard
    Lip, Gregory Y. H.
    CURRENT MEDICINAL CHEMISTRY, 2016, 23 (19) : 2055 - 2069
  • [46] Atrial fibrillation: Stroke prevention in focus
    Ferguson, Caleb
    Inglis, Sally C.
    Newton, Phillip J.
    Middleton, Sandy
    Macdonald, Peter S.
    Davidson, Patricia M.
    AUSTRALIAN CRITICAL CARE, 2014, 27 (02) : 92 - 98
  • [47] Anticoagulation: Stroke Prevention in Patients with Atrial Fibrillation
    Waldo, Albert L.
    CARDIOLOGY CLINICS, 2009, 27 (01) : 125 - +
  • [48] The Use of Dabigatran for Prevention of Thromboembolic Complications in Patients Underwent Atrial Fibrillation Catheter Ablation
    Mamchur, S. E.
    Gorbunova, E. V.
    Sherbinina, D. A.
    Romanova, M. P.
    KARDIOLOGIYA, 2015, 55 (04) : 30 - 35
  • [49] Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation
    Providencia, Rui
    Marijon, Eloi
    Albenque, Jean-Paul
    Combes, Stephane
    Combes, Nicolas
    Jourda, Francois
    Hireche, Hassiba
    Morais, Joao
    Boveda, Serge
    EUROPACE, 2014, 16 (08): : 1137 - 1144
  • [50] Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis
    Van Der Meersch, Hans
    De Bacquer, Dirk
    De Vriese, An S.
    AMERICAN HEART JOURNAL, 2017, 184 : 37 - 46
12345